Referanslar

1. Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014;24(5):645-692. [Crossref]  [PubMed]
2. McCleery A, Nuechterlein KH. Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations . Di alogues Clin Neurosci. 2019;21(3):239-248. [Crossref]  [PubMed]  [PMC]
3. García-Laredo, E. Cognitive impairment in schizophrenia: description and cognitive familiar endophenotypes. A review of the literature. IntechOpen, 2018. [Crossref]  [PubMed]
4. Vita A, Gaebel W, Mucci A, et al. European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia. Eur Psychiatry. 2022;65(1):e58. Published 2022 Sep 5. [Crossref]  [PubMed]  [PMC]
5. Harvey PD. Domains of cognition and their assessment . Dialogues Clin Neurosci. 2019;21(3):227-237. [Crossref]  [PubMed]  [PMC]
6. Helldin L, Mohn C, Olsson AK, Hjärthag F. Neurocognitive variability in schizophrenia spectrum disorders: relationship to real-world functioning. Schizophr Res Cogn. 2020;20:100172. Published 2020 Feb 14. [Crossref]  [PubMed]  [PMC]
7. McCutcheon RA, Keefe RSE, McGuire PK. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment [published correction appears in Mol Psychiatry. 2023 May;28(5):1919. Mol Psychiatry. 2023;28(5):1902-1918. [Crossref]  [PubMed]  [PMC]
8. Palmer BW, Dawes SE, Heaton RK. What do we know about neuropsychological aspects of schizophrenia?. Neuropsychol Rev. 2009;19(3):365-384. [Crossref]  [PubMed]  [PMC]
9. Sadock BJ. Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. 8 ed. vol 2. Güneş Kitabevi Ltd.Şti; 2007. [Crossref]  [PubMed]
10. Fatouros-Bergman H, Cervenka S, Flyckt L, Edman G, Farde L. Meta-analysis of cognitive performance in drug-naïve patients with schizophrenia. Schizophr Res. 2014;158(13):156-162. [Crossref]  [PubMed]
11. Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology. 2009;23(3):315-336. [Crossref]  [PubMed]
12. Fioravanti M, Bianchi V, Cinti ME. Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence. BMC Psychiatry. 2012;12:64. Published 2012 Jun20. [Crossref]  [PubMed]  [PMC]
13. Gebreegziabhere Y, Habatmu K, Mihretu A, Cella M, Alem A. Cognitive impairment in people with schizophrenia: an umbrella review. Eur Arch Psychiatry Clin Neurosci. 2022;272(7):1139-1155. [Crossref]  [PubMed]  [PMC]
14. Schaefer J, Giangrande E, Weinberger DR, Dickinson D. The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr Res. 2013;150(1):42-50. [Crossref]  [PubMed]  [PMC]
15. Bowie CR, Leung WW, Reichenberg A, et al. Predicting schizophrenia patients’ real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry. 2008;63(5):505-511. [Crossref]  [PubMed]  [PMC]
16. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?. Schizophr Bull. 2000;26(1):119-136. [Crossref]  [PubMed]
17. Keefe RS. Should cognitive impairment be included in the diagnostic criteria for schizophrenia?. World Psychiatry. 2008;7(1):22-28. [Crossref]  [PubMed]  [PMC]
18. Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry. 2007;64(5):532-542. [Crossref]  [PubMed]
19. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12(3):426-445. [Crossref]  [PubMed]
20. Hill SK, Schuepbach D, Herbener ES, Keshavan MS, Sweeney JA. Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naïve patients with schizophrenia. Schizophr Res. 2004;68(1):49-63. [Crossref]  [PubMed]
21. Hughes C, Kumari V, Soni W, et al. Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophr Res. 2003;59(2-3):137-146. [Crossref]  [PubMed]
22. Reichenberg A, Harvey PD, Bowie CR, et al. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr Bull. 2009;35(5):10221029. [Crossref]  [PubMed]  [PMC]
23. Rajji TK, Ismail Z, Mulsant BH. Age at onset and cognition in schizophrenia: meta-analysis. Br J Psychiatry. 2009;195(4):286-293. [Crossref]  [PubMed]
24. Vaskinn A, Sundet K, Simonsen C, Hellvin T, Melle I, Andreassen OA. Sex differences in neuropsychological performance and social functioning in schizophrenia and bipolar disorder. Neuropsychology. 2011;25(4):499-510. [Crossref]  [PubMed]
25. Bozikas VP, Andreou C. Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. Aust N Z J Psychiatry. 2011;45(2):93-108. [Crossref]  [PubMed]
26. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72(1):41-51. [Crossref]  [PubMed]
27. Buchanan RW, Carpenter WT. Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis. 1994;182(4):193-204. [Crossref]  [PubMed]
28. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005;31(1):5-19. [Crossref]  [PubMed]
29. Dickinson D, Harvey PD. Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr Bull. 2009;35(2):403-414. [Crossref]  [PubMed]  [PMC]
30. Faber G, Smid HG, Van Gool AR, Wunderink L, Wiersma D, van den Bosch RJ. Neurocognition and recovery in first episode psychosis. Psychiatry Res. 2011;188(1):1-6. [Crossref]  [PubMed]
31. Keefe RS. The longitudinal course of cognitive impairment in schizophrenia: an examination of data from premorbid through posttreatment phases of illness. J Clin Psychiatry. 2014;75 Suppl 2:8-13. [Crossref]  [PubMed]
32. Rajji TK, Miranda D, Mulsant BH. Cognition, function, and disability in patients with schizophrenia: a review of longitudinal studies. Can J Psychiatry. 2014;59(1):13-17. [Crossref]  [PubMed]  [PMC]
33. Reichenberg A. The assessment of neuropsychological functioning in schizophrenia. Dialogues Clin Neurosci. 2010;12(3):383-392. [Crossref]  [PubMed]  [PMC]
34. Kircher T, Whitney C, Krings T, Huber W, Weis S. Hippocampal dysfunction during free word association in male patients with schizophrenia. Schizophr Res. 2008;101(13):242-255. [Crossref]  [PubMed]
35. Takei K, Yamasue H, Abe O, et al. Disrupted integrity of the fornix is associated with impaired memory organization in schizophrenia. Schizophr Res. 2008;103(1-3):52-61. [Crossref]  [PubMed]
36. Brekke JS, Raine A, Ansel M, Lencz T, Bird L. Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia. Schizophr Bull. 1997;23(1):19-28. [Crossref]  [PubMed]
37. Goldman-Rakic PS. Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci. 1994;6(4):348-357. [Crossref]  [PubMed]
38. Keefe RS. Working memory dysfunction and its relevance to schizophrenia. Cognition in schizophrenia. 2000:16-50. [Crossref]  [PubMed]
39. Silver H, Feldman P, Bilker W, Gur RC. Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am J Psychiatry. 2003;160(10):1809-1816. [Crossref]  [PubMed]
40. Brekke J, Kay DD, Lee KS, Green MF. Biosocial pathways to functional outcome in schizophrenia. Schizophr Res. 2005;80(2-3):213-225. [Crossref]  [PubMed]
41. Brüne M. “Theory of mind” in schizophrenia: a review of the literature. Schizophr Bull. 2005;31(1):21-42. [Crossref]  [PubMed]
42. Green AI, Zimmet SV, Strous RD, Schildkraut JJ. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?. Harv Rev Psychiatry. 1999;6(6):287-296. [Crossref]  [PubMed]
43. Vauth R, Rüsch N, Wirtz M, Corrigan PW. Does social cognition influence the relation between neurocognitive deficits and vocational functioning in schizophrenia?. Psychiatry Res. 2004;128(2):155-165. [Crossref]  [PubMed]
44. Pinkham AE, Harvey PD, Penn DL. Social Cognition Psychometric Evaluation: Results of the Final Validation Study. Schizophr Bull. 2018;44(4):737-748. [Crossref]  [PubMed]  [PMC]
45. Pinkham AE, Penn DL, Green MF, Buck B, Healey K, Harvey PD. The social cognition psychometric evaluation study: results of the expert survey and RAND panel. Schizophr Bull. 2014;40(4):813-823. [Crossref]  [PubMed]  [PMC]
46. Hooker C, Park S. Emotion processing and its relationship to social functioning in schizophrenia patients. Psychiatry Res. 2002;112(1):41-50. [Crossref]  [PubMed]
47. Addington J, Addington D. Facial affect recognition and information processing in schizophrenia and bipolar disorder. Schizophr Res. 1998;32(3):171-181. [Crossref]  [PubMed]
48. Aakre JM, Seghers JP, St-Hilaire A, Docherty N. Attributional style in delusional patients: a comparison of remitted paranoid, remitted nonparanoid, and current paranoid patients with nonpsychiatric controls. Schizophr Bull. 2009;35(5):994-1002. [Crossref]  [PubMed]  [PMC]
49. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151(10):14091416. [Crossref]
50. Jääskeläinen E, Juola P, Hirvonen N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39(6):1296-1306. [Crossref]  [PubMed]  [PMC]
51. Addington J, Addington D, Maticka-Tyndale E. Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophr Res. 1991;5(2):123-134. [Crossref]  [PubMed]
52. Dominguez Mde G, Viechtbauer W, Simons CJ, van Os J, Krabbendam L. Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. Psychol Bull. 2009;135(1):157-171. [Crossref]
53. Nieuwenstein MR, Aleman A, de Haan EH. Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. Wisconsin Card Sorting Test. Continuous Performance Test. J Psychiatr Res. 2001;35(2):119-125. [Crossref]  [PubMed]
54. Keefe RS, Harvey PD. Cognitive impairment in schizophrenia. Handb Exp Pharmacol. 2012;(213):11-37. [Crossref]  [PubMed]
55. Davidson M, Galderisi S, Weiser M, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST) [published correction appears in Am J Psychiatry. 2009 Jun;166(6):731]. Am J Psychiatry. 2009;166(6):675-682. [Crossref]  [PubMed]
56. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64(6):633-647. [Crossref]  [PubMed]
57. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162(10):1785-1804. [Crossref]  [PubMed]
58. Rund BR, Barder HE, Evensen J, et al. Neurocognition and Duration of Psychosis: A 10-year Follow-up of First-Episode Patients. Schizophr Bull. 2016;42(1):87-95. [Crossref]  [PubMed]  [PMC]
59. Brissos S, Dias VV, Balanzá-Martinez V, Carita AI, Figueira ML. Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Schizophr Res. 2011;129(2-3):133-136. [Crossref]  [PubMed]
60. Emsley R, Rabinowitz J, Medori R; Early Psychosis Global Working Group. Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates. Schizophr Res. 2007;89(1-3):129-139. [Crossref]  [PubMed]
61. Helldin L, Kane JM, Karilampi U, Norlander T, Archer T. Remission and cognitive ability in a cohort of patients with schizophrenia. J Psychiatr Res. 2006;40(8):738-745. [Crossref]  [PubMed]
62. Hofer A, Bodner T, Kaufmann A, et al. Symptomatic remission and neurocognitive functioning in patients with schizophrenia. Psychol Med. 2011;41(10):2131-2139. [Crossref]  [PubMed]
63. Johansson M, Hjärthag F, Helldin L. Cognitive markers related to long-term remission status in Schizophrenia Spectrum Disorders. Psychiatry Res. 2020;289:113035.
64. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry. 2001;58(1):24-32. [Crossref]  [PubMed]
65. Reichenberg A. Cognitive impairment as a risk factor for psychosis. Dialogues Clin Neurosci. 2005;7(1):31-38. [Crossref]  [PubMed]  [PMC]
66. Khandaker GM, Barnett JH, White IR, Jones PB. A quantitative meta-analysis of population-based studies of premorbid intelligence and schizophrenia. Schizophr Res. 2011;132(23):220-227. [Crossref]  [PubMed]  [PMC]
67. Dauvermann MR, Donohoe G. The role of childhood trauma in cognitive performance in schizophrenia and bipolar disorder A systematic review. Schizophr Res Cogn. 2018;16:1-11. Published 2018 Dec 11. [Crossref]  [PubMed]  [PMC]
68. Reinharth J, Reynolds G, Dill C, Serper M. Cognitive predictors of violence in schizophrenia: a meta-analytic review. Schizophrenia Research: Cognition. 2014;1(2):101-111. [Crossref]
69. Millgate E, Hide O, Lawrie SM, Murray RM, MacCabe JH, Kravariti E. Neuropsychological differences between treatment-resistant and treatment-responsive schizophrenia: a meta-analysis. Psychol Med. 2022;52(1):1-13. [Crossref]  [PubMed]  [PMC]
70. Irani F, Kalkstein S, Moberg EA, Moberg PJ. Neuropsychological performance in older patients with schizophrenia: a meta-analysis of cross-sectional and longitudinal studies. Schizophr Bull. 2011;37(6):1318-1326. [Crossref]  [PubMed]  [PMC]
71. Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet. 1994;344(8934):1398-1402. [Crossref]  [PubMed]
72. Brekke JS, Hoe M, Long J, Green MF. How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia. Schizophr Bull. 2007;33(5):12471256. [Crossref]  [PubMed]  [PMC]
73. Cornblatt B, Obuchowski M, Roberts S, Pollack S, Erlenmeyer-Kimling L. Cognitive and behavioral precursors of schizophrenia. Dev Psychopathol. 1999;11(3):487-508. [Crossref]  [PubMed]
74. Seidman LJ, Giuliano AJ, Meyer EC, et al. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry. 2010;67(6):578-588. [Crossref]  [PubMed]  [PMC]
75. Seidman LJ, Giuliano AJ, Meyer EC, et al. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry. 2010;67(6):578-588. [Crossref]  [PubMed]  [PMC]
76. Sheffield JM, Karcher NR, Barch DM. Cognitive Deficits in Psychotic Disorders: A Lifespan Perspective. Neuropsychol Rev. 2018;28(4):509-533. [Crossref]  [PubMed]  [PMC]
77. Fusar-Poli P, Bonoldi I, Yung AR, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012;69(3):220-229. [Crossref]  [PubMed]
78. Bora E, Murray RM. Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis?. Schizophr Bull. 2014;40(4):744-755. [Crossref]  [PubMed]  [PMC]
79. Bergh S, Hjorthøj C, Sørensen HJ, et al. Predictors and longitudinal course of cognitive functioning in schizophrenia spectrum disorders, 10years after baseline: The OPUS study. Schizophr Res. 2016;175(1-3):57-63. [Crossref]  [PubMed]
80. Green MF, Harvey PD. Cognition in schizophrenia: Past, present, and future. Schizophr Res Cogn. 2014;1(1):e1-e9. [Crossref]  [PubMed]  [PMC]
81. Malla AK, Takhar JJ, Norman RM, et al. Negative symptoms in first episode non-affective psychosis. Acta Psychiatr Scand. 2002;105(6):431-439. [Crossref]  [PubMed]
82. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004;72(1):29-39.
83. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry. 1996;153(3):321-330. [Crossref]  [PubMed]
84. McGurk SR, Mueser KT, Harvey PD, LaPuglia R, Marder J. Cognitive and symptom predictors of work outcomes for clients with schizophrenia in supported employment. Psychiatr Serv. 2003;54(8):1129-1135. [Crossref]  [PubMed]
85. Lysaker P, Bell M, Beam-Goulet J. Wisconsin card sorting test and work performance in schizophrenia. Psychiatry Res. 1995;56(1):45-51. [Crossref]  [PubMed]
86. McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr Res. 2000;45(3):175-184. [Crossref]  [PubMed]
87. Leung WW, Bowie CR, Harvey PD. Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: A cross-sectional study. J Int Neuropsychol Soc. 2008;14(3):479-488. [Crossref]  [PubMed]  [PMC]
88. Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophr Bull. 2018;44(6):1195-1203. [Crossref]  [PubMed]  [PMC]
89. George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000;157(11):1835-1842. [Crossref]  [PubMed]
90. Brown EC, Tas C, Can H, Esen-Danaci A, Brüne M. A closer look at the relationship between the subdomains of social functioning, social cognition and symptomatology in clinically stable patients with schizophrenia. Compr Psychiatry. 2014;55(1):25-32. [Crossref]  [PubMed]
91. Fett AK, Viechtbauer W, Dominguez MD, Penn DL, van Os J, Krabbendam L. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev. 2011;35(3):573-588. [Crossref]  [PubMed]
92. Mueser KT, Doonan R, Penn DL, et al. Emotion recognition and social competence in chronic schizophrenia. J Abnorm Psychol. 1996;105(2):271-275. [Crossref]  [PubMed]
93. Addington J, Addington D. Neurocognitive and social functioning in schizophrenia. Schizophr Bull. 1999;25(1):173-182. [Crossref]  [PubMed]
94. Kim CH, Jayathilake K, Meltzer HY. Hopelessness, neurocognitive function, and insight in schizophrenia: relationship to suicidal behavior. Schizophr Res. 2003;60(1):71-80. [Crossref]  [PubMed]
95. Tolman AW, Kurtz MM. Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. Schizophr Bull. 2012;38(2):304-315. [Crossref]  [PubMed]  [PMC]
96. Snitz BE, Macdonald AW 3rd, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull. 2006;32(1):179-194. [Crossref]  [PubMed]  [PMC]
97. Gur RE, Calkins ME, Gur RC, et al. The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes. Schizophr Bull. 2007;33(1):49-68. [Crossref]  [PubMed]  [PMC]
98. Bortolato B, Miskowiak KW, Köhler CA, Vieta E, Carvalho AF. Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses. Neuropsychiatr Dis Treat. 2015;11:3111-3125. Published 2015 Dec17. [Crossref]  [PubMed]  [PMC]
99. Bora E, Yucel M, Pantelis C. Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: meta-analytic study. Br J Psychiatry. 2009;195(6):475-482. [Crossref]  [PubMed]
100. Bora E, Özerdem A. Meta-analysis of longitudinal studies of cognition in bipolar disorder: comparison with healthy controls and schizophrenia. Psychol Med. 2017;47(16):27532766. [Crossref]  [PubMed]
101. Heaton R, Paulsen JS, McAdams LA, et al. Neuropsychological deficits in schizophrenics. Relationship to age, chronicity, and dementia. Arch Gen Psychiatry. 1994;51(6):469-476. [Crossref]  [PubMed]
102. Ozbek SU, Sut E, Bora E. Comparison of social cognition and neurocognition in schizophrenia and autism spectrum disorder: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2023;155:105441.